1361390-71-7

Basic information

• Product Name: C₆₅H₇₅N₄O₁₂PSi
• CAS NO: 1361390-71-7
• Molecular Weight: 1163.39
• Mol File: 1361390-71-7.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: C₆₅H₇₅N₄O₁₂PSi(CAS DataBase Reference)
• NIST Chemistry Reference: C₆₅H₇₅N₄O₁₂PSi(1361390-71-7)
• EPA Substance Registry System: C₆₅H₇₅N₄O₁₂PSi(1361390-71-7)

Safety Data

• Hazardous Substances Data: 1361390-71-7(Hazardous Substances Data)

Upstream product

• 144490-31-3 5'-O-(4,4'-dimethoxytrityl)-2'-O-(tert-butyldimethylsilyl)uridine-3'-[(2-cyanoethyl)-(N,N-diisopropyl)]phosphoramidite 
• 68392-35-8 4-hydroxytamoxifen 

Relevant articles and documents

Ribonuclease-activated cancer prodrug

Cancer chemotherapeutic agents often have a narrow therapeutic index that challenges the maintenance of a safe and effective dose. Consistent plasma concentrations of a drug can be obtained by using a timed-release prodrug strategy. We reasoned that a ribonucleoside 3′-phosphate could serve as a pro-moiety that also increases the hydrophilicity of a cancer chemotherapeutic agent. Herein, we report an efficient route for the synthesis of the prodrug uridine 3′-(4-hydroxytamoxifen phosphate) (UpHT). UpHT demonstrates timed-released activation kinetics with a half-life of approximately 4 h at the approximate plasma concentration of human pancreatic ribonuclease (RNase 1). MCF-7 breast cancer cells treated with UpHT showed decreased proliferation upon coincubation with RNase 1, consistent with the release of the active drug-4-hydroxytamoxifen. These data demonstrate the utility of a human plasma enzyme as a useful activator of a prodrug.